Sökning: WFRF:(Kristjánsson Gudjón)
> (2012) >
IgA Nephropathy – Mucosal Immunity and Treatment Options
-
- Smerud, Hilde Kloster (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Fellström, Bengt, Professor (preses)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Kristjansson, Gudjon, MD, PhD (preses)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
visa fler...
-
- Hällgren, Roger, Professor (preses)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- de Fijter, Johan W., Professor (opponent)
- Leiden University Medical Center
-
visa färre...
-
(creator_code:org_t)
- ISBN 9789155482862
- Uppsala : Acta Universitatis Upsaliensis, 2012
- Engelska 69 s.
-
Serie: Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 1651-6206 ; 744
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- In the present studies we have explored the link between food hypersensitivity and IgA nephropathy (IgAN) and evaluated treatment options in primary and recurrent disease. Approximately one third of our IgAN patients had a rectal mucosal sensitivity to gluten, as demonstrated by increased local mucosal nitric oxide production and/or myeloperoxidase release after gluten challenge. The gluten sensitivity seemed to be an innate immune reaction unrelated to the pathogenesis of celiac disease. Approximately half of the patients had a rectal mucosal sensitivity to soy or cow’s milk (CM). The levels of IgG antibodies to alfa-lactalbumin, beta-lactoglobulin and casein were significantly higher in CM sensitive as compared with non-sensitive IgAN patients, indicating that an adaptive immune response might be involved in addition to the innate immune reaction observed. With the knowledge of gastrointestinal reactivity enteric treatment was considered as a potential new treatment approach of IgAN. A 6-month prospective trial demonstrated proof-of-concept for the use of enteric budesonide targeted to the ileocaecal region of IgAN patients. We observed a modest, but significant reduction in urine albumin, a minor reduction of serum creatinine and a modest increase of eGFR calculated by the MDRD equation. eGFR calculated from the Cockcroft-Gault formula and cystatin C was not changed. In a retrospective study recurrence of IgAN and graft loss was evaluated in Norwegian and Swedish patients having received a primary renal transplant due to IgAN. Adjusting for relevant covariates, a multiple Cox-regression analysis on time to IgAN recurrence showed that use of statins was associated with reduced risk of recurrence and reduced risk of graft loss. The time lag from diagnosis to first transplantation and female gender were also associated with lower risk of recurrence. Improved graft survival was associated with related donor, low donor age and no or low number of acute rejection episodes.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- IgA nephropathy
- mucosal immunity
- gastrointestinal sensitivity
- food allergens
- pharmacological treatment
- budesonide
- statin
- clinical trial
- renal transplantation
- recurrence
- Internal Medicine
- Internmedicin
Publikations- och innehållstyp
- vet (ämneskategori)
- dok (ämneskategori)